MetLife (MET) Stock Could Be 42% Undervalued Despite Policy Settlement News

MetLife has delivered a strong long run for shareholders over the past few years, which naturally puts the focus on whether that price performance is backed by the returns the insurer earns on its capital. With the stock now changing hands close to US$100, the key issue for investors is how that market value lines up with what the business is actually generating on the capital it employs.

• Over the last 5 years the share price has gained 82.5%, which raises a clear question about whether the underlying returns on capital can support that kind of wealth creation.

• The recent approval of a C$213.5 million settlement related to certain universal life policies sold by MetLife agents in Canada may influence future cash flows, since it affects both compensation paid out and ongoing policy fee structures.

• What if you looked at MetLife through its earnings instead? See why MetLife's 18.5x P/E tells a different valuation story .

The issue now is whether the current MetLife share price is appropriately aligned with the returns it earns on its capital.

If you want to stress test whether MetLife's recent 5 year return of 82.5% lines up with the returns it earns on capital, line it up against 29 high quality undervalued stocks .

Is MetLife Still Cheap on Excess Returns?

The Excess Returns model looks at how efficiently MetLife turns its equity base into profits above the return investors require. In this view, the insurer is treated as a business that can keep reinvesting at a certain rate on its book value, rather than just as a stream of cash flows. Book value sits at $43.03 per share, with a stable book estimate of $51.92 per share, so the framework leans on a sizeable equity cushion.

MetLife's stable EPS input of $8.39 per share against a cost of equity of $3.85 per share produces an excess return of $4.54 per share, supported by an average return on equity of 16.16%. The Excess Returns projections put MetLife's estimated intrinsic value substantially above the current share price of $99.98. The Ontario class action settlement related to universal life policies, while large in headline terms, helps explain why the price stays below the value implied by these excess returns since it highlights legal and cash flow uncertainties that some investors may be baking into the stock. Find out what MetLife could be worth using our Excess Returns estimate .

The MetLife Narrative: What Would Justify Today's Price?

Narratives pick up where MetLife's valuation puzzle leaves off by explaining which future growth paths, profitability levels and earnings patterns would need to occur for the stock to trade meaningfully higher or lower than it does today. Each scenario connects its figures to a specific view on how MetLife's expansion, margin profile and risk picture might change over time, giving you a reference point you can revisit as new information becomes available.